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Background: Micro-albuminuria is a recognized predictor of cardiovascular morbidity and mortality in patients with
coronary artery disease. We have previously reported, in diabetic and non-diabetic patients, that an increased
urinary excretion of IgM is associated with higher cardiovascular mortality. The purpose of this study was to
investigate the pattern of urinary IgM excretion in patients with acute coronary syndrome (ACS) and its correlation
to cardiovascular outcome.
Methods: Urine albumin, and IgM to creatinine concentration ratios were determined in 178 consecutive patients
presenting with chest pain to the Department of Emergency Medicine (ED) at the University Hospital of Lund. Fifty
eight (23 female) patients had ACS, 55 (19 female) patients had stable angina (SA), and 65 (35 female) patients were
diagnosed as non-specific chest pain (NS).
Results: Urine albumin and IgM excretions were significantly higher in patients with ACS (p = 0.001, and p = 0.029,
respectively) compared to patients with NS-chest pain. During the 2 years follow-up time, 40 (19 female) patients
suffered a new major cardiovascular event (ACS, acute heart failure, stroke) and 5 (4 male/1 female) patients died of
cardiovascular cause. A high degree of albuminuria and IgM-uria significantly predicted cardiovascular mortality and
morbidity (HR = 2.89, 95% CI: 1.48 - 5.66, p = 0.002). Microalbuminuric patients (≥3mg/mmol) with high IgM-uria
(≥0.005mg/mmol) had a 3-fold higher risk for cardiovascular new events compared to patients with low IgM-uria
(RR = 3.3, 95% CI: 1.1 - 9.9, p = 0.001).
Conclusion: In patients with chest pain, an increased urine IgM excretion, is associated with coronary artery disease
and long-term cardiovascular complications. Measuring urine IgM concentration could have a clinical value in risk
stratification of patients with ACS.
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The number of patients presenting to the emergency de-
partment (ED) with symptoms consistent with acute cor-
onary syndrome (ACS) is rising [1,2]. Medical history
and ECG findings are widely used and reliable keystones
in risk stratification of patients presenting with chest
pain [3,4]. However, many patients who are admitted to
the medical ward due to chest pain will not turn out to
suffer from acute coronary syndrome (ACS) [5]. Thus
better tools for risk stratification are needed.
ACS is associated with increased urinary albumin excre-
tion [6,7]. Microalbuminuria (MA) has been recognized as* Correspondence: Omran.Bakoush@med.lu.se
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reproduction in any medium, provided the oran independent prognostic marker for poor outcome in
patients with coronary artery disease (CAD) [8]. MA could
reflect widespread endothelial dysfunction due to athero-
sclerotic disease [9], with relative lack of endothelial nitric
oxide (NO) production and increased levels of oxidative
stress [10]. Long-term follow up studies on proteinuric pa-
tients have revealed that IgM-uria may be associated with
a higher risk for cardiovascular (CV) mortality [11-13].
For instance, type 2 diabetic patients with MA and IgM-
uria had a 3-fold higher risk for CV mortality than pa-
tients with merely MA. To the best of our knowledge,
IgM-uria has not been studied in patients with CAD.
Therefore, in this cohort of patients presenting with chest
pain to the emergency department (ED) we studied the
diagnostic and prognostic value of IgM-uria.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Consecutive patients presenting with symptoms suggest-
ive of ACS, to the ED at Skåne University Hospital in
Lund during 53 daytime working shifts between September
1st and December 31st 2010, were invited to participate
in the study. The study was carried out in compliance
with the Helsinki Declaration, and was approved
by the Regional Ethical Review Board of Lund (Dnr
2009/441).
After informed consent, 178 (77 female) consecutive
patients with chest pain were included in the study. The
patients were further assessed by the attending phys-
ician. The physician assessment included history, phys-
ical examination, 12-lead electrocardiography (ECG) and
cardiac Troponin T (TNT) assay. Vital signs were mea-
sured in supine position at admission to the ED. Mean
arterial blood pressure (MAP) was calculated by addingTable 1 Baseline characteristics and two-year cardiovascular o




Age, yr 76 (52-98)
Sex, n 35/23
P. creatinine, μmol/L 86.5 (56-249)





DM (type 1/type 2) 10 (2/8)
LDL cholesterol, mmol/L 3 (1.3-5.4)
TGL, mmol/L 1.25 (0.6-6.6)
P. IgM, g/l 0.76 (0.2-3.5)
IgM-uria, mg/mmol 0.0066
(0.00027-0.249)
Albuminuria, mg/mmol 2 (0.1-247)
IgG-uria, mg/mmol 2.1 (0.1-89)
CRP, mg/l 3.1 (0.6-80)
TNT, ng/l 24 (5-1168)
Admitted, n (m/f ) 53 (34/19)
CV outcome at 2 years follow up, n (m/f ) 27 (16/11)
Death = 3 (2/1)
AMI = 8(5/3)
Angina = 9(5/4)
CVI = 1 (0/1)
HF = 6 (4/2)
MAP: mean arterial pressure, BMI: body mass index, Admitted: number of patients
ratio, CRP: C-reactive protein, TNT: Troponin T. LDL cholesterol: low density lipoprone third of the pulse pressure to the diastolic blood pres-
sure. All participants were asked at the time of admission
to provide urine samples for urine protein analysis.
65 patients (35 female) with normal 12-lead ECGs and
normal plasma TNT levels were discharged to go home
after a few hours of observation in the ED (Table 1). 113
(46 female) patients were admitted to the medical ward
with suspected acute coronary syndrome (ACS). Cardiac
stress test (including exercise test or myocardial scintig-
raphy) was done in ambiguous cases (n = 36).
The final diagnosis was retrieved from the discharge
notes of the patient’s medical records. Patients who were
diagnosed with ACS were those with acute ST-elevation
(STEMI) or non ST-elevation myocardial infarction
(NSTEMI) or unstable angina. Patients with a previous
history of cardiovascular event (angina, acute myocardial
infarction (AMI), stroke), with no emerging ECG changesutcome of 178 patients presented with chest pain to the
e clinical diagnosis of coronary artery disease
Stable Angina Non-specific chest pain P value
(ACS vs. NS)(SA) (NS)
n = 55 n = 65
70 (39-91) 62 (40-92) <0.001
36/19 30/35 0.1
85 (49-259) 75 (49-166) <0.001
105 (81-140) 105 (82-140) 0.7




18 (0/18) 6 (0/6) 0.2
2.2 (1-5) 3.2 (1.8-5) 0.5
1.25 (0.6-3.5) 1.55 (0.7-4) 0.2
0.73 (0.05-1.5) 0.71 (0.27-4.9) 0.9
0.0058 0.0046 0.029
(0.00075-0.0549) (0.00098-0.0716)
0.6 (0.1-59) 0.1 (0.1-70) 0.001
1.6 (0.1-6.6) 1.6 (0.1-11) 0.06
1.4 (0.6-24) 1.6 (0.6-33) 0.012
9 (5-419) 5 (5-44) <0.001
28 (16/12) 32 (17/15) <0.001
12 (6/6) 6 (3/3) <0.001
Death = 2(2/0) Death = 0
AMI = 3(1/2) AMI = 3(2/1)
Angina = 3(1/2) Angina = 1 (0/1)
CVI = 0 CVI = 1(1/0)
HF = 4(2/2) HF = 1 (0/1)
admitted to hospital. DM: Diabetes mellitus, IgM-uria: Urine IgM creatinine
otein cholesterol level, TGL: triglycerides level.
Table 2 Univariate cox-regression analysis for two-year
cardiovascular outcome of 178 patients presented with
chest pain to the emergency department
Variable Beta SE P-value HR 95% CI
Age (2 groups) 0.86 0.32 0.007 2.37 1.26-4.46
Hypertension (yes/no) 0.79 3.33 0.018 2.22 1.14-4.29
Prev. cv disease (yes/no) 1.33 3.37 <0.001 3.78 1.82-7.85
DM (yes/no) −0.48 0.44 0.27 0.62 0.26-1.46
Dyslipidemia (yes/no) −0.25 0.32 0.43 0.78 0.42-1.45.
hs-CRP (2 groups) 0.65 0.30 0.034 1.91 1.05-3.48
Plasma TNT (2 groups) 0.7 0.32 0.026 2.02 1.09-3.76
S. creatinine (2 groups) 0.24 0.3 0.43 1.27 0.71-2.29
Albuminuria (2 groups) 0.99 0.30 0.001 2.68 1.48-4.85
IgM-uria (2 groups) 1.08 0.34 0.001 2.96 1.52-5.77
Beta: Regression coefficient, SE: Standrad error of regression, HR: Hazard
ratio, 95% CI: 95% confidence interval, DM: Diabetes mellitus, IgM-uria: Urine
IgM creatinine ratio, hs-CRP: High sensitive C-reactive protein, TNT: Troponin
T. Prev. cv disease: Previous cardiovascular disease.
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(SA). Patients with atypical anginal chest pain with no his-
tory of previous cardiovascular event with normal ECG
and TNT series were diagnosed as non-specific chest pain
(NS).
The patients were followed up to the end of February
2012 for occurrence of any major cardiovascular event
such as death, MI, and stroke. Cardiovascular death was
defined as all deaths where unequivocal non-CV death
was not established.
Laboratory methods
The plasma and urine creatinine (enzymatic method),
serum and urine proteins, and serum lipids were ana-
lyzed at the Central Clinical Chemistry Laboratory at the
University Hospital in Lund, for details see [14,15]. Pa-
tients were defined as having dyslipidemia if serum low
density lipoprotein cholesterol >3 mmol/L and/or serum
triglycerides level >1.7 mmol/L [16]. Urinary albumin
concentration was measured by immunoturbidometry
on fresh urine samples taken at the time of patient ad-
mission. We used a Cobas Mira S system (Roche Inc.)
and monospecific rabbit antisera obtained from Dako
(Copenhagen, Denmark). Urine samples were stored in
3.5-ml polypropene tubes and kept at –20C until ana-
lysis for IgM. Urine IgM concentrations were measured
by an ELISA technique described in detail elsewhere
[17]. The lower detection limit for the urine IgM assay is
1 μg/l; the intra-assay and inter-assay variation is 4.6%
and 10.9%, respectively.
Urine albumin, and IgM are presented as albumin, and
IgM-creatinine ratios mg/mmol (ACR and MCR), respect-
ively. The lowest detection level of ACR is 0.1 mg/mmol.
The median value of urine IgM concentration of the whole
cohort was 0.005 mg/mmol. Patients were divided into low
and high IgM-uria groups according to the cohort median
concentration.
Statistical methods
Data are presented as medians (and ranges). Statistically
significant levels were set considering 95% confidence in-
tervals (CI) and a P value <0.05. Kruskal–Wallis H and
Mann-Whitney U tests were used to compare groups.
Kaplan–Meier curves (for survival analysis) and Log Rank
test were used to assess differences in survival. Cox-
proportional hazards regression analysis was employed to
assess the association of baseline variables and cardiovas-
cular outcome. Patients with missing data were excluded.
All statistical analyses were performed by using IBM SPSS
statistics for Windows, version 17.0 (SPSS).
Results
Fifty eight (23 female) patients had acute coronary syn-
drome. 3 (1 female) patients with STEMI, 25 (8 female)with NSTEMI and 30 (14 female) patients had unstable
angina. Fifty five (19 female) patients had SA. Sixty five
(35 female) patients were diagnosed as NS.
There was no difference in gender, mean arterial blood
pressure, smoking, and family history of IHD between pa-
tients with ACS and NS chest pain (Table 1). Patients with
ACS were older with higher prevalence of hypertension,
worse kidney function and higher hs-CRP than NS pa-
tients. Urine albumin and urine IgM excretions were
higher in patients with ACS than those with NS (p = 0.001
and p = 0.029, respectively), as shown in Table 1. However,
there was no difference in urine IgM or urine albumin ex-
cretion between patients with SA and NS (P = 0.3, P = 0.2,
ns) or between patients who performed the stress test or
not (P = 0.3, P = 0.5, ns).
During a 2 year follow-up, 5 (1 female) patients died
from a cardiovascular cause and 40 (19 female) patients
suffered a new major cardiovascular event, (Table 1).
Albumiuria and IgM-uria in risk stratification of patients
with chest pain
By univariate Cox-regression analysis the predictors for
major cardiovascular events were: age (HR = 1.031), hyper-
tension (HR = 2.38), previous ischemic heart disease (HR =
4.33) hs-CRP (HR = 1.87), TNT (HR = 2.02), albuminuria
(HR = 1.87), and IgM-uria (HR = 2.96), Table 2. Dia-
betes, dyslipidemia, and level of kidney function were
not associated with the cardiovascular outcome in this
cohort (Table 2).
In a multivariate Cox-regression analysis, a significant
association remained between IgM-uria and the cardio-
vascular outcome even after adjustment for key poten-
tial confounding variables: age, hypertension, previous
Figure 1 Two-year cardiovascular outcome of 178 patients
presented with chest pain stratified by the degree of IgM uria.
A: patients with normo-albuminuria (ACR < 3 mg/mmol). B: patients
with albuminuria (ACR > 3 mg/mmol).
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(HR = 2.1, 95% CI 1.05–4.01, p = 0.04).
In Kaplan Meier curve analysis, patients with MA
(≥3 mg/mmol) and high levels of IgM-uria (≥0.0054 mg/
mmol) had a three-fold higher risk of new cardiovascular
events than patients with MA and low-grade IgM-uria
(RR = 3.3, 95% CI: 1.1-9.9, p = 0.001) (Figure 1).
Discussion
In this prospective study, we found that patients who
presented to the ED with chest pain due to acute coronary
artery disease had a higher level of MA and IgM-uria
than those with non-specific chest pain. Indeed, IgM-uria
was associated with a higher risk of occurrence of subse-
quent major cardiovascular events. Furthermore, IgM-uria
predicted poor long term cardiovascular outcome, inde-
pendently of levels of MA, kidney function, diabetes and
hypertension.
Under normal conditions the glomerular filtration bar-
rier (GFB) allows just tiny amounts of albumin (molecu-
lar radius 35.5 Å) to pass to the primary urine, just one
molecule out of 10,000 [18]. More than 97% of the fil-
tered molecules are normally subsequently reabsorbed
by the proximal tubules [19,20]. However, the GFB is
not a static filter, but rather a highly dynamic sieve,
which can directly increase its permeability in systemic
inflammation [21], after trauma [22], during hypergly-
cemia [23], or following elevations of circulating ANP
(atrial natriuretic peptide) levels [24], or angiotensin II
levels [25]. Our data strongly suggest that albumin and
other large proteins, such as IgG (mol. radius 55 Å) and
IgM (mol. radius 120 Å) are able to pass the GFB only
through large size-selective defects, “large pores” (shunts).
An increased number of such shunt-like pores will func-
tionally form in all of the pathophysiological conditions
listed above resulting in albuminuria, IgG-uria and
IgM-uria, while, at least initially, urinary tubular mar-
kers will stay unchanged. Consequently, the increased
urinary IgM concentrations seen in patients with CAD
must be secondary to decreases in size-selectivity of the
GFB. Such size-selective defects are likely to be caused
by endothelial dysfunction (due to atherosclerosis),
acute systemic inflammation and/or ischemic (or HF-
induced) release of ANP [20,24,26]. This is further
strengthened by the fact that elevations of hs-CRP, ref-
lecting systemic inflammation associated with athero-
sclerosis [27], and troponin T, more reflecting cardiac
muscle ischemia, were coupled to the presence of CAD
[28,29] and to MA and IgM-uria, in turn signaling a
poor cardiovascular outcome [12,13]. Unfortunately, it
is likely that the method for assessing IgG urine concen-
tration may not have been sensitive enough compared
with the methods for MA and IgM-uria, since IgG-uria
was not as strongly coupled to predictions of outcomeas were MA and IgM-uria. Urine IgM analysis is a sim-
ple, non-invasive urine test that could be incorporated
in the routine laboratory analysis, for risk stratification
of patients with chest pain [5,30]. Addition of urine IgM
analysis to the workup of patients with coronary artery
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recurrent cardiovascular events. This prompts early
introduction of an intensive multifactorial preventive
treatment strategy to improve the overall cardiovascular
risk profile [31].
The study is limited by its observational nature. It was
conducted in one centre and the participants were al-
most only of Scandinavian origin. However, our study
has more than a few strengths. First, the patients were
included prospectively and consecutively. Second, the
study has a relatively long follow up time. Third, there
was no loss of subjects during the follow up. Further-
more, urine IgM was measured during the first doctor
contact in the ED.
Conclusion
In conclusion, patients with chest pain, with MA and
high levels of IgM-uria carry a higher probability for cor-
onary artery disease and a poorer long-term cardiovas-
cular outcome than patients with low IgM-uria. A larger
longitudinal confirmatory study is needed to evaluate
the usefulness of urine IgM in risk stratification of pa-
tients with Coronary Artery Disease.
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